Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances

Vanda Pharmaceuticals1,000 enrolled

Overview

This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Sleep Disturbances in Smith-Magenis Syndrome

Interventions

Data collection of sleep disturbances in individuals with SMSOTHER

Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey

Eligibility

Sex: ALLMin age: 3 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Parent or legal guardian of individual with Smith-Magenis Syndrome Exclusion Criteria: * Not legal guardian of individual with SMS

Locations (1)

Vanda Pharmaceuticals

Washington D.C., District of Columbia, United States

RECRUITING

Outcomes

Primary Outcomes

Number of individuals with Smith- Magenis syndrome

Time frame: 5 years

Secondary Outcomes

Sleep Disturbances

Time frame: Up to 100 weeks

Central Contacts

Vanda Pharmaceuticals

CONTACT

202-734-3400 clinicaltrials@vandapharma.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.